A Randomized Controlled Trial of Four Precolonoscopy Bowel Cleansing Regimens by Kao, Dina et al.
Can J Gastroenterol Vol 25 No 12 December 2011 657
A randomized controlled trial of four precolonoscopy 
bowel cleansing regimens
Dina Kao MD FRCPC1, Eoin Lalor MBCHB FRCPC1, Gurpal Sandha FRCPC1, Richard N Fedorak MD FRCPC1,  
Bloeme van der Knoop BSc2, Stieneke Doornweerd BSc2, Harmke van Kooten BSc3, Eline Schreuders BSc3,  
William Midodzi PhD4, Sander Veldhuyzen van Zanten MD FRCPC1
1Division of Gastroenterology, University of Alberta, Edmonton, Alberta; 2Free University of Amsterdam, Amsterdam;3Erasmus University, Rotterdam,  
The Netherlands; 4Patient Research Centre, Memorial University, St John’s, Newfoundland and Labrador
Correspondence: Dr Dina Kao, 2-24B Zeidler Building, University of Alberta, Edmonton, Alberta T6G 2X8. Telephone 780-492-8307,  
fax 780-492-8121, email dkao@ualberta.ca
Received for publication March 31, 2011. Accepted July 29, 2011
Adequate bowel preparation is essential for successful colonos-copy. Unfortunately, despite advances in technology and phar-
macology, inadequate bowel cleansing outcomes continue to frustrate 
physicians and patients. Suboptimal bowel preparation not only pro-
longs procedure time and reduces completion rate, but also increases 
the likelihood of lesions being missed, especially those in the right 
colon (1).
For years, polyethylene glycol (PEG) was regarded as the ‘gold 
standard’. However, the large volume of the PEG preparation (4 L), its 
salty taste and sulphur smell frequently reduce patient acceptance and 
compliance, thus resulting in suboptimal bowel preparation (2,3). 
Given its low volume and good efficacy, sodium phosphate (NaP) was 
popular among clinicians and patients in the past (4-6); however, NaP 
use can lead to significant fluid and electrolyte shifts, and acute phos-
phate nephropathy (7-11).
Other bowel cleansing regimens that have been examined include 
sodium picosulphate plus magnesium oxide-containing preparations 
(PSMC, Pico-Salax [Ferring Pharmaceuticals Inc, Canada]) and low-
volume PEG, alone or in combination with an adjunct such as bisacodyl 
(B) and magnesium citrate (M). Although these regimens are reported 
to be safe and well-tolerated by patients (12), their cleansing efficacy 
remains uncertain because, to date, only a small number of studies have 
been published (13-15). One recent randomized controlled trial (16) 
reported that PSMC + B was superior to either PSMC alone or NaP, 
specifically in the right colon.
A meta-analysis published in 2006 (6) examined 18 studies com-
paring PEG (n=1629) to NaP (n=1855), three studies comparing PEG 
(n=104) with PSMC (n=112) and three studies comparing NaP 
(n=369) with PSMC (n=381). It concluded that NaP was more effect-
ive than either high-volume PEG or PSMC. It also concluded that 
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BACKGrounD: The ideal bowel cleansing regimen for colonoscopy 
has yet to be determined.
oBJECtivE: To compare the cleansing efficacy, and patient tolerabil-
ity and safety of four bowel preparation regimens. 
mEthoDS: A total of 834 patients undergoing outpatient colonos-
copy were randomly assigned to one of four regimens: 4 L polyethylene 
glycol (PEG); 2 L PEG + 20 mg bisacodyl; 90 mL of sodium phosphate 
(NaP); or two sachets of a commercially available bowel cleansing 
solution (PSMC) + 300 mL of magnesium citrate (M). The primary 
outcome measure was cleansing efficacy, which was scored by blinded 
endoscopists using the Ottawa Bowel Preparation Scale. Secondary 
outcome measures were bowel preparation quality according to time of 
colonoscopy, and patient tolerability and safety.
rESuLtS: The mean total cleansing score was significantly worse in 
the NaP group compared with the other three groups (P<0.0001). The 
mean cleansing scores were worse in patients who underwent morning 
versus afternoon colonoscopy, a finding that was consistent in all four 
groups. PSMC + M was the best tolerated regimen. No clinically sig-
nificant mean changes in creatinine or electrolyte levels were identi-
fied, although a significantly higher proportion of patients in the NaP 
group developed hypokelemia (P<0.0001). 
ConCLuSionS: 2 L PEG + 20 mg bisacodyl, or PSMC + M was as 
efficacious as 4 L PEG and superior to NaP for bowel cleansing. A short 
interval between the completion of bowel preparation and the start of 
colonoscopy (ie, ‘runway time’), irrespective of bowel preparation 
regimen, appeared to be a more important predictor of bowel cleanli-
ness than the cathartic agents used.
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un essai aléatoire et contrôlé de quatre régimes de 
nettoyage intestinal avant une coloscopie
hiStoriQuE : Le régime de nettoyage intestinal idéal en vue de la 
coloscopie n’a pas encore été déterminé. 
oBJECtiF : Comparer l’efficacité du nettoyage, la tolérabilité des 
patients et l’innocuité de quatre régimes de préparation intestinale.
mÉthoDoLoGiE : Au total, 834 patients qui ont subi une coloscopie 
en consultations externes ont été répartis au hasard entre l’un des quatre 
régimes suivants : 4 L de polyéthylène glycol (PEG), 2 L de PEG + 20 mg 
de bisacodyl, 90 mL de phosphate de sodium (NaP) ou deux sachets 
d’une solution de nettoyage intestinal (PSMC) offerte sur le marché + 
300 mL de citrate de magnésium (M). La mesure d’issue primaire était 
l’efficacité du nettoyage, notée en aveugle par des endoscopistes au 
moyen de l’échelle de préparation intestinale d’Ottawa. Les mesures 
d’issue secondaire étaient la qualité de la préparation intestinale d’après 
le moment de la coloscopie, la tolérabilité des patients et l’innocuité.
rÉSuLtAtS : L’indice de nettoyage total moyen était beaucoup 
moins bon dans le groupe de NaP que dans les trois autres groupes 
(P<0,0001). Les indices de nettoyage moyens étaient pires chez les 
patients qui subissaient la coloscopie le matin plutôt que l’après-midi, 
une observation uniforme dans les quatre groupes. Le régime le mieux 
toléré était le PSMC + M. Les chercheurs n’ont remarqué aucun 
changement moyen significatif sur le plan clinique des taux de créati-
nine ou d’électrolytes, même si une proportion considérablement plus 
élevée de patients du groupe de NaP a présenté une hypokaliémie 
(P<0,0001).
ConCLuSionS : 2 L de PEG + 20 mg de bisacodyl ou le PSMC + M 
étaient aussi efficaces que 4 L de PEG et supérieurs au NaP pour le net-
toyage intestinal. Un court intervalle entre la fin de la préparation 
intestinale et le début de la coloscopie (c’est-à-dire le « temps d’activité »), 
quelle que soit la préparation intestinale utilisée, semblait être un pré-
dicteur plus important de la propreté intestinale que le type d’agents 
cathartiques utilisés.
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PEG and PSMC were similar in efficacy. However, a 2007 systematic 
review of 24 trials comparing PEG (n=2107) with NaP (n=1984) (12) 
concluded that there was no significant difference in efficacy between 
these two regimens (OR 1.0 [95% CI 0.67 to 1.5]). There are little 
data available on how low-volume PEG or PSMC compare with NaP 
(17,18).
Furthermore, factors other than cathartic agents themselves have 
been shown to influence bowel preparation quality. The interval at 
which the cleansing agents are taken has been shown to affect this 
outcome (19-21). For example, two doses of NaP taken 12 h or 24 h 
apart result in better bowel preparations than two doses taken 6 h 
apart (19). Data have shown better quality bowel preparation to follow 
from morning (AM), rather than afternoon (PM), colonoscopies 
(20,22,23). This association appeared to be inversely related to the 
duration of the interval between the completion of bowel preparation 
and the start of colonoscopy (also referrred to as ‘runway time’), as 
described by Siddiqui et al (24) and others (25,26). The optimal ‘run-
way time’ appeared to be 4 h to 8 h.
The objectives of the present study were to compare both AM and 
PM colonoscopies for the following outcomes: cleansing efficacy; 
patient tolerability; and the safety of 4 L PEG, 2L PEG + B, NaP and 
PSMC + M.
mEthoDS
Protocol
The present prospective, randomized, endoscopist-blinded study was 
conducted at the University of Alberta Hospital (Edmonton, Alberta). 
The study was approved by the Health Research Ethics Board of the 
University of Alberta and registered with clinicaltrials.gov 
(NCT00831064). Informed consent was obtained from each patient 
before enrollment. Ambulatory gastroenterology clinic patients between 
18 and 75 years of age who underwent elective outpatient colonoscopy 
were recruited for participation. Patients with the following conditions 
were excluded: renal insufficiency or abnormal creatinine clearance 
(glomerular filtration rate <59 mL/L); congestive heart failure; recent 
acute coronary syndrome or unstable angina; liver cirrhosis or ascites; 
chronic furosemide therapy; previous colorectal resection; and known or 
suspected bowel obstruction, megacolon or ileus.
Assignment
Participants were randomly assigned to receive one of four bowel cleans-
ing regimens before colonoscopy: group 1 received 4 L PEG (4L PEG); 
group 2 received 2 L PEG + 20 mg of B (2 L PEG+B); group 3 received 
two doses of 45 mL NaP 24 h apart; and group 4 received PSMC + 300 
mL of M (PSMC+M). In January 2009, NaP was voluntarily with-
drawn by the manufacturers in Canada; therefore, allocation to this 
arm was terminated. Patients who had previously been randomly 
assigned to this arm were randomly re-assigned to one of the other 
groups.
Participants were instructed to ingest a clear fluid diet on the day 
before colonoscopy; they were also given explicit instruction to 
hydrate liberally with water or a clear electrolyte replacement solution 
until 2 h before the procedure. Written cleansing procedure instruc-
tion sheets were given to all participants.
Participants who were scheduled to undergo colonoscopy between 
08:00 and 12:00 (AM colonoscopy) and between 12:30 and 17:00 (PM 
colonoscopy) took their preparations according to the schedules in 
Table 1. The schedules were designed in such a way so that they were 
convenient for participants to follow, and the interval between the 
completion of bowel preparation and the start of colonoscopy were as 
similar as possible for the AM and PM groups.
masking
Eight experienced endoscopists participated in the present study. 
Randomization of the bowel preparation allocation was conducted 
using blocks of eight, and stratified according to AM and PM colonos-
copy using a computer-generated table of random numbers. The con-
cealment of allocation was maintained through the use of consecutively 
numbered, sealed, opaque envelopes.
Analysis
The main hypothesis of the present study was that one of the four 
commonly used bowel cleansing preparations was superior with respect 
to cleansing efficacy. The primary outcome measure was the quality of 
bowel preparation, which was assessed using the total Ottawa Bowel 
Preparation Scale (OBPS). Each endoscopist measured the quality of 
bowel preparation using the OBPS, which has been shown to be a 
valid and reliable tool for assessing bowel cleansing (27). It uses ratings 
from 0 to 4 (0 = excellent to 4 = inadequate) for assessment of the 
right, middle and rectosigmoid colon, and includes a separate score for 
overall fluid (0 to 2). These four individual scores are added, and the 
total score of between 0 and 14 provides a global assessment of bowel 
preparation quality. An excellent bowel preparation is judged to 
have a total score of 0 to 1, while a good bowel preparation has a 
score of 2 to 4 (27). To ensure that similar criteria were used to rate 
bowel preparation quality, an experienced clinician independently 
trained all endoscopists in advance of the present trial.
The secondary outcomes assessed were cleanliness score for indi-
vidual OBPS components (right, middle, and rectosigomid colon and 
fluid level); differences within bowel preparation groups according to 
colonoscopy timing; patient tolerance of preparations, assessed by a 
questionnaire that included questions about symptom severity (nau-
sea, vomiting, chest pain, and abdominal cramps or distension); ability 
to complete bowel preparation; number of hours slept the night before 
colonoscopy and willingness to repeat the same bowel preparation; 
and safety of bowel preparation, as assessed by changes in serum elec-
trolyte (sodium, potassium, calcium and phosphate) and creatinine 
levels before and after the bowel preparation, as well as the number of 
patients with ischemic colitis – a recently reported rare complication 
of B (28,29). Patient tolerance was assessed by categorical outcomes on 
symptoms and ability to complete the preparation (mild to moderate, or 
severe to intolerable), willingness to repeat the same preparation (yes or 
no), and by 7-point Likert scales on other outcomes.
Sample size calculation and data analyses
A 2-point difference between the mean scores for bowel preparation 
on the OBPS was considered to be the minimal clinically significant 
difference. A sample size of 732 was estimated to be necessary to yield 
80% power at a two-sided alpha of 0.05 to detect this difference. To 
allow for a 15% dropout rate and incomplete colonoscopy, the final 
sample size was calculated to be 840.
Table 1
bowel cleansing schedules, according to group, for 
morning (aM) and afternoon (PM) colonoscopy
Group 1 (AM) 
4L PEG 
4 L PEG over 4 h starting at 18:00 on the day before 
colonoscopy
Group 2 (AM)  
2L PEG+B
20 mg B at 16:00 + 2 L PEG over 2 h starting at 20:00 
on the day before colonoscopy
Group 3 (AM) 
NaP
45 mL NaP at 20:00 two days before colonoscopy +  
45 mL NaP at 20:00 on the day before colonoscopy
Group 4 (AM) 
PSMC+M
One sachet of PSMC at 08:00 and at 14:00 + 300 mL M  
at 20:00 on the day before colonoscopy
Group1 (PM)  
4L PEG
2L PEG at 20:00 on the day before colonoscopy +  
2L PEG at 06:00 on the day of colonoscopy
Group 2 (PM)  
2L PEG+B 
20 mg B at 20:00 on the day before colonoscopy +  
2L PEG at 06:00 on the day of colonoscopy 
Group 3 (PM) 
NaP
45 mL NaP at 06:00 on the day before colonoscopy +  
45 mL NaP at 06:00 on the day of colonoscopy
Group 4 (PM)
PSMC+M
One sachet of PSMC at 18:00 and at 22:00 on the day 
before colonoscopy + 300 mL M at 06:00 on the day of 
colonoscopy
B Bisacodyl; M Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene 
glycol; PSMC Pico-Salax (Ferring Pharmaceuticals Inc, Canada) 
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The mean total OBPS scores and individual OBPS components 
were analyzed as a continuous variable using one-way ANOVA tests 
with correction for multiple comparisons. Differences in bowel prep-
aration according to time of colonoscopy (AM or PM) and effects of 
sex and age on preparation quality were assessed post hoc. A separate 
post hoc analysis was also performed using c2 analysis to determine the 
proportion of patients in each group with total OBPS scores of greater 
than 5.
Tolerability was analyzed using the Mantel-Haenszel test. All other 
variables were described as mean ± SD, and compared using one-way 
ANOVA, or described as counts and percentages. Regression analyses 
were used to determine possible interactions among OBPS, age and 
sex.
rESuLtS
A total of 834 patients were enrolled in the present study between 
September 2007 and July 2009 (Figure 1). There were no significant 
differences among the study groups in baseline characteristics (Table 2). 
Fifty-six patients were excluded from the primary analyses: 44 with-
drew before undergoing the assigned cleansing regimens, and 12 due to 
technical difficulties preventing the completion of the OBPS. Four 
patients underwent incomplete colonoscopy due to poor bowel prep-
aration (group 1: n=1, and group 2: n=3) and were assigned the  max-
imum OBPS score of 14. One hundred and fifteen patients were 
excluded from tolerability analyses due to missing questionnaire data, 
while 329 patients were excluded from safety analyses due to missing 
postcolonoscopy electrolyte and creatinine data. The missing data 
were equally divided among the four groups.
Cleansing efficacy
Colonoscopy cleansing data were obtained for 778 patients. The mean 
total score was significantly higher in the NaP group than in the other 
three groups (Table 3), although the mean differences between the 
groups did not reach 2, which was predetermined to be the minimal 
Table 2
baseline characteristics according to preparation group* 
Preparation group
P4 l PeG 2 l PeG+b NaP PSMC+M
n 218 214 164 194 –
Age, years 49.8 50.8 49.6 48.4 0.368
Male, % 41.7 35.2 39.8 40.7 0.551
Morning colonoscopy, % 63.8 63.6 61.0 62.4 0.946
*Morning and afternoon colonoscopy groups combined. B Bisacodyl; M 
Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene glycol; PSMC 
Pico-Salax (Ferring Pharmaceuticals Inc, Canada)
        Total participants 
              (N= 834) 
4L PEG 
(N’ 1= 218) 
2L PEG+B 
(N’ 2=214) 
NaP 
(N’ 3= 164) 
PSMC+M 
(N’ 4=194) 
44 participants dropped out prior 
to taking preparation 
N2= 210 N3= 164 N4= 194 
8 excluded for 
incomplete 
colonoscopy 
due to 
technical 
reasons  
4 excluded for  
incomplete 
colonoscopy 
due to 
technical 
reasons 
N1= 210 
Figure 1) Consolidated Standards of Reporting Trials study flow chart. B 
Bisacodyl; M Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene 
glycol; PSMC Pico-Salax (Ferring Pharmaceuticals Inc, Canada) 
Table 3
Mean bowel Ottawa bowel Preparation Scale cleansing 
scores according to colonoscopy preparation group
Morning and afternoon colonoscopy groups combined
Preparation group
P*
4l PeG 
(n=210)
2l PeG+b 
(n=210)
NaP 
(n=164)
PSMC+M 
(n=194)
Right colon 1.35 1.10 2.04 1.37 <0.0001†
Middle colon 0.89 0.82 1.24 0.88 0.001‡
Rectosigmoid 
colon 0.96 0.86 1.13 0.71 0.007§
Overall fluid 0.62 0.66 0.46 0.54 0.002¶
Total score  
(95% CI)
3.72 
(3.29- 4.14)
3.36 
(2.99-3.73)
4.83 
(4.35-5.32)
3.46 
(3.08-3.84) <0.0001**
*Corrected for multiple comparisons; †Significant difference between NaP and 
4 L PEG, between NaP and 2 L PEG+B, and between NaP and PSMC; 
‡Significant difference between NaP and 4L PEG, between NaP and 2 L 
PEG+B, and between NaP and PSMC. §Significant difference between NaP 
and PSMC; ¶Significant difference between NaP and 2 L PEG+B; **Significant 
difference between NaP and 4L PEG, between NaP and 2 L PEG+B, and 
between NaP and PSMC. B Bisacodyl; M Magnesium citrate; NaP Sodium 
phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring 
Pharmaceuticals Inc, Canada)
Morning colonoscopy
Preparation group
P*
4l PeG 
(n=134)
2l PeG + b 
(n=136)
NaP 
(n=100)
PSMC + M 
(n=121)
Right colon 1.49 1.17 2.38 1.58 <0.0001†
Middle colon 1.00 0.87 1.37 1.02 0.002‡
Rectosigmoid 
colon
1.09 0.94 1.30 0.80 0.004§
Overall fluid 0.56 0.56 0.33 0.46 0.12
Total score 
(95%CI)
4.14 
(3.63-4.64)
3.51 
(3.06-3.96)
5.37 
(4.80-5.94)
3.84 
(3.35-4.34)
<0.0001¶
*Corrected for multiple comparisons; †Significant difference between NaP and 
4L PEG, between NaP and 2L PEG+B, and between NaP and PSMC; 
‡Significant difference between NaP and 4L PEG, between NaP and 2L PEG 
+ B, and between NaP and PSMC; §Significant difference between NaP and 
4L PEG, between NaP and 2L PEG + B, and between NaP and PSMC. 
¶Significant difference between NaP and 4L PEG, between NaP and 2L PEG 
+ B, and between NaP and PSMC. B Bisacodyl; M Magnesium citrate; NaP 
Sodium phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring 
Pharmaceuticals Inc, Canada)
afternoon colonoscopy
Preparation group
P
4l PeG 
(n=76)
2l PeG + b 
(n=74)
NaP 
(n=64)
PSMC + M 
(n=73)
Right colon 0.85 0.92 1.39 0.96 0.920
Middle colon 0.57 0.69 0.89 0.64 0.212
Rectosigmoid  
colon
0.61 0.68 0.72 0.56 0.711
Overall fluid 0.61 0.8 0.51 0.67 0.083
Total score 
 (95%CI)
2.59 
(2.00-3.18)
3.08 
(2.42-3.75)
3.51 
(2.84-4.18)
2.82 
(2.24-3.40)
0.220
B Bisacodyl; M Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene 
glycol; PSMC Pico-Salax (Ferring Pharmaceuticals Inc, Canada)
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clinically significant difference. The NaP group was the only group 
with a total mean OBPS score >4, which represented a less than ‘good’ 
bowel preparation (24). In addition, the NaP group also had the high-
est proportion of patients (29%) with total scores >5 compared with 
the other groups: 4 L PEG (19%), 2 L PEG+B (17%) and PSMC 
(15%) (P=0.004). The mean total scores were significantly higher for 
the AM compared with the PM colonoscopies, a finding that was 
consistent across all four groups (Table 3), even after adjusting for sex 
and age (P=0.65).
The right colon was consistently more difficult to clean in all 
groups, especially when the colonoscopy was performed in the mor-
ning (Table 3). Interestingly, differences in total OBPS scores and 
scores for various colonic segments between groups were small and not 
statistically significant when colonoscopies were performed in the PM 
(Table 3).
Patient tolerance of preparations
There were no significant group differences for reported symptoms of 
nausea, vomiting, abdominal cramping, bloating or chest pain (Table 4). 
Significantly fewer patients reported mild or moderate dizziness after 
taking 2 L PEG+B compared with the other groups (Table 4). Patients 
in the NaP group slept longer the night before colonoscopy (6.81 h) 
than did those in the other three groups (5.73 h, 5.13 h and 5.21 h, 
respectively [P<0.0001]). More patients assigned to 4 L PEG and 2L 
PEG+B found it difficult to complete the preparations than did those 
assigned to NaP or PSMC+M (P<0.0001). More patients assigned to 
PEG-based regimens preferred a different regimen in the future 
(Figure 2) than those assigned to take NaP or PSMC+M. A signifi-
cantly higher proportion of patients assigned to PSMC+M found the 
taste of the cleansing agent to be more tolerable than in the other 
three groups (P<0.0001). The mean overall tolerability score was the 
lowest for the 4 L PEG group (4.19) compared with that of the other 
three groups (4.60, 4.75 and 4.66, respectively [P<0.011]).
Patient safety
There were no clinically significant changes in mean electrolyte or cre-
atinine levels in any of the study groups (Table 5). However, a signifi-
cantly higher proportion of patients (10.6%) with potassium levels of 
lower than 3 mmol/L was observed in the NaP group than in the other 
three groups. Six per cent of patients in the NaP group developed hyper-
phosphatemia (phosphate >2.0 mmol/L), a finding that was not seen in 
any other group. Hypocalcemia (calcium <2.2 mmol/L) was frequent in 
the NaP group (25%), although it was also seen in the 4L PEG group 
(18%). After taking the cathartic agent, 21 patients experienced a rise 
in creatinine levels of 20 μmol/L or more compared with baseline (4L 
PEG, n=4; 2L PEG+B, n=6; NaP, n=2 and PSMC+M, n=9), although 
none of these patients’ creatinine levels actually reached an abnormal 
value. No cases of ischemic colitis were identified.
Table 5
Mean changes (∆) from baseline in serum electrolyte and 
creatinine levels
Parameter
Colonoscopy preparation group
P
4l PeG
(n=117)
2l PeG + b
(n=135)
NaP
(n=99)
PSMC + M
(n=129)
∆Na, mmol/L 1.87 2.51 2.05 2.48 0.011
Serum Na  
>145 mmol/L*, n (%)
1 (0.6) 0 (0) 0 (0) 1 (0.6) 0.332
∆K, mmol/L 0.74 0.65 0.80 0.57 <0.0001
Serum K  
<3.0 mmol/L*, n (%)
1 (0.6) 0 (0) 11 (11) 1 (0.6) <0.0001
∆Cl, mmol/L 2.85 3.14 3.77 3.41 0.61
∆Ca, mmol/L 0.075 0.089 0.081 0.084 0.259
   Serum Ca  
<2.2 mmol/L*, n (%)
21 (18) 9 (7) 25 (25) 7 (5) <0.0001
∆PO4, mmol/L 0.17 0.16 0.36 0.18 <0.001
 Serum PO4  
>2.0 mmol/L*, n (%)
0 (0) 0 (0) 6 (6) 0 (0) <0.0001
∆Creatinine, μmol/L 9.04 9.32 7.52 9.96 0.074
Rise in creatinine  
≥20 μmol/L*, n (%)
2 (2) 4 (3) 1 (1) 6 (5) 0.0681
*Abnormal laboratory value. B Bisacodyl; M Magnesium citrate; NaP Sodium 
phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring 
Pharmaceuticals Inc, Canada) 
Table 4
Regimen tolerability: Reported patient symptoms for morning and afternoon colonoscopy groups combined
Symptom
4l PeG (n=184) 2l PeG + b (n=179) NaP (n=153) PSMC + M (n=178)
PMild-moderate Severe Mild-moderate Severe Mild-moderate Severe Mild-moderate Severe
Nausea 86 (46.9) 8 (4.5) 68 (37.9) 10 (5.6) 67 (43.9) 6 (4.1) 74 (41.6) 4 (2.2) 0.444
Vomiting 20 (10.6) 4 (2.2) 15 (8.5) 5 (2.8) 8 (5.4) 1 (0.7) 16 (9.0) 3 (1.7) 0.515
Abdominal cramps 77 (41.9) 6 (3.4) 67 (37.3) 9 (5.1) 62 (40.5) 5 (3.4) 67 (37.6) 3 (1.7) 0.634
Bloating 95 (51.4) 11 (6.1) 77 (42.9) 6 (3.4) 58 (37.8) 8 (5.4) 66 (37.1) 7 (3.9) 0.051
Chest pain 6 (3.4) 1 (0.6) 6 (3.4) 0 (0) 6 (4.1) 0 (0) 5 (2.8) 1 (0.6) 0.901
Dizziness 40 (21.8) 1 (0.6) 18 (10.2) 3 (1.7) 40 (26.4) 0 (0) 50 (28.2) 3 (1.7) 0.001*
Data presented as n (%) unless otherwise indicated. *Corrected for multiple comparisons. Significant difference between 4 L PEG and 2L PEG+B, between 2 L PEG 
+ B, between 2L PEG + B and PSMC + M. B Bisacodyl; M Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring 
Pharmaceuticals Inc, Canada)
Figure 2) Percentage of patients who would rather try a different regimen in 
the future according to group (P<0.0001). M Magnesium citrate; NaP 
Sodium phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring 
Phamaceuticals Inc, Canada) 
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DiSCuSSion
The results of the present study demonstrate that NaP, although 
favoured by patients and clinicians in the past, is inferior to 4 L PEG, 
2 L PEG + B and PSMC + M in cleansing efficacy, although the dif-
ference did not reach the predetermined minimal clinically significant 
score of 2. Previous studies using the OBPS have also found the score 
differences between PEG and NaP and between PSMC and NaP to be 
less than 2 and, therefore, one could argue that the statistically signifi-
cant differences observed in bowel preparation quality following differ-
ent cleansing regimens may not be clinically significant (16,19). In the 
present study, the NaP group also had a significantly higher proportion 
of patients with less than ideal bowel preparations compared with the 
other three groups. Given the added risks of electrolyte disturbance 
and acute phosphate nephropathy, NaP should not be used as a cleans-
ing agent, especially because more effective alternatives are available. 
In fact, the NaP manufacturer has voluntarily withdrawn this product 
from the market in the United States and in Canada.
The bowel preparation schedules were designed so that the inter-
vals between the completion of bowel preparation and the start of 
colonoscopy (ie, ‘runway time’) were as similar and convenient as pos-
sible for the AM and PM procedures in all groups. For practical rea-
sons, the start time of 20:00 (18:00 for 4 L PEG) was chosen for 
commencing the preparation the night before the procedure for AM 
colonoscopies, and 06:00 for the PM procedures. The consequence of 
this bowel preparation schedule was shorter intervals for the PM 
colonoscopies (4 h to 8 h) compared with AM colonoscopies (10 h to 
14 h). This is the likely explanation for the better overall bowel prep-
aration quality of the PM colonoscopies, irrespective of the purging 
regimens. Furthermore, the observed group differences in bowel prep-
aration quality in AM colonoscopies (ie, NaP was the worst group 
among the four regimens) was not present in the PM colonoscopies, 
suggesting that ‘runway time’ may be a more important factor than the 
cathartic agents used in determining bowel cleanliness. There are now 
emerging data suggesting that same-day preparation may improve the 
quality of bowel cleansing for afternoon colonoscopy (30,31), again 
reflecting the fact that shorter runway time is critical for a good bowel 
preparation.
Several studies have shown that split-dose preparations are more 
efficacious than single-dose regimens (32-35). In fact, the most current 
colon cancer screening guidelines from the American College of 
Gastroenterology (36) recommended split-dose regimens. However, 
split-dosing in a regimen requires patients scheduled for AM colonos-
copy to rise in the early hours of the day to finish the final cathartic 
dose, likely decreasing compliance, especially if patients are not suffi-
ciently educated about the importance of a good bowel preparation. 
Interestingly, Gupta et al (37) have shown that prior-day dosing disrupts 
sleep and travel to the endoscopy units to the same degree as split dos-
ing. Experts believe that most patients would comply with split-dosing 
schedules by getting up early – just as they would for other important 
reasons (38) – if they were given the right information. The reason bet-
ter bowel preparations may be more effective with a split-dose regimen 
may be explained by a shorter runway time.
Patient factors may also have an impact on the quality of bowel 
preparation. For example, obesity (body mass index >30 kg/m2) and 
chronic constipation have been shown to be independent predictors of 
inadequate bowel preparation (39,40).
The combination of PSMC + M was rated the best-tolerated regi-
men from the perspective of taste, ease of completion and a low fre-
quency of symptoms with ingestion, compared with PEG-based 
regimens or NaP. PSMC + M also appeared to be safe, with very few 
associated cases of hypokelemia or hypocalcemia, although our sample 
size was not large enough to specifically address safety concerns. A 
PSMC-based regimen could be a good low-volume bowel preparation 
alternative.
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